PMID- 27662818
OWN - NLM
STAT- MEDLINE
DCOM- 20180105
LR  - 20210109
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Print)
IS  - 0306-5251 (Linking)
VI  - 83
IP  - 3
DP  - 2017 Mar
TI  - Utility of serum anti-cetuximab immunoglobulin E levels to identify patients at a 
      high risk of severe hypersensitivity reaction to cetuximab.
PG  - 623-631
LID - 10.1111/bcp.13140 [doi]
AB  - AIM: Cetuximab is an anti-epidermal growth factor receptor antibody used for the 
      treatment of metastatic colorectal cancer and head and neck cancer. 
      Hypersensitivity reactions (HSRs) are associated with cetuximab use. The aim of 
      the study was to evaluate the utility of anti-cetuximab immunoglobulin E (IgE) 
      detection in order to identify patients at risk of HSR to cetuximab. METHODS: We 
      included patients ready to receive a first cetuximab infusion in a prospective 
      cohort carried out at nine French centres. Pretreatment anti-cetuximab IgE levels 
      were measured. We compared the proportion of severe HSRs in the low 
      anti-cetuximab IgE levels (</=29 IgE arbitrary units) subgroup with that in a 
      historical cohort of 213 patients extracted from a previous study. RESULTS: Of 
      the 301 assessable patients (mean age: 60.9 +/- 9.3 years, head-and-neck cancer: 
      77%), 66 patients (22%) had high anti-cetuximab IgE levels, and 247 patients 
      received cetuximab (including 38 with high anti-cetuximab levels). Severe HSRs 
      occurred in eight patients (five grade 3 and three grade 4). The proportion of 
      severe HSRs was lower in the low anti-cetuximab IgE levels subgroup vs. the 
      historical cohort (3/209 [1.4%] vs. 11/213 [5.2%], odds ratio, 0.27, 95% 
      confidence interval, 0.07-0.97), and higher in high vs. low anti-cetuximab IgE 
      levels subgroup (5/38 [13.2%] vs. 3/209 [1.4%]; odds ratio, 10.4, 95% confidence 
      interval, 2.4-45.6). Patients with severe HSRs had higher anti-cetuximab IgE 
      levels than patients without reaction (median, 45 vs. 2 IgE arbitrary units, 
      P = 0.006). CONCLUSIONS: Detection of pretreatment anti-cetuximab IgE is feasible 
      and helpful to identify patients at risk of severe cetuximab-induced HSRs.
CI  - (c) 2016 The British Pharmacological Society.
FAU - Dupont, Benoit
AU  - Dupont B
AD  - Department of Hepato-Gastroenterology and Nutrition, CHU de Caen, Caen, France.
FAU - Mariotte, Delphine
AU  - Mariotte D
AD  - Laboratory of Immunology and Immunopathology, CHU de Caen, Caen, France.
FAU - Dugue, Audrey E
AU  - Dugue AE
AD  - Clinical Research Department, Centre Francois Baclesse, Caen, France.
FAU - Clarisse, Benedicte
AU  - Clarisse B
AD  - Clinical Research Department, Centre Francois Baclesse, Caen, France.
FAU - Grellard, Jean-Michel
AU  - Grellard JM
AD  - Clinical Research Department, Centre Francois Baclesse, Caen, France.
FAU - Babin, Emmanuel
AU  - Babin E
AD  - Department of Otolaryngology-Head and Neck Surgery, CHU de Caen, Caen, France.
FAU - Chauffert, Bruno
AU  - Chauffert B
AD  - Medical Oncology Department, CHU d'Amiens, Amiens, France.
FAU - Dakpe, Stephanie
AU  - Dakpe S
AD  - Department of Maxillofacial Surgery and Stomatology, CHU d'Amiens, Amiens, 
      France.
FAU - Moldovan, Cristian
AU  - Moldovan C
AD  - Medical Oncology Department, Centre Henri Becquerel, Rouen, France.
FAU - Bouhier-Leporrier, Karine
AU  - Bouhier-Leporrier K
AD  - Department of Hepato-Gastroenterology and Nutrition, CHU de Caen, Caen, France.
FAU - Reimund, Jean-Marie
AU  - Reimund JM
AD  - Department of Hepato-Gastroenterology and Nutrition, CHU de Caen, Caen, France.
AD  - Department of Hepato-Gastroenterology and Nutritional Support, CHU de Strasbourg, 
      Strasbourg, France.
FAU - Di Fiore, Frederic
AU  - Di Fiore F
AD  - Medical Oncology Department, Centre Henri Becquerel, Rouen, France.
AD  - Digestive Oncology Unit, Gastroenterology Department, CHU de Rouen, Rouen, 
      France.
FAU - Zanetta, Sylvie
AU  - Zanetta S
AD  - Medical Oncology Department, Centre Georges-Francois Leclerc, Dijon, France.
FAU - Mailliez, Audrey
AU  - Mailliez A
AD  - Head and Neck Department, Centre Oscar Lambret, Lille, France.
FAU - Do, Pascal
AU  - Do P
AD  - Medical Oncology Department, Centre Francois Baclesse, Caen, France.
FAU - Peytier, Annie
AU  - Peytier A
AD  - Gastroenterology Department, Centre Hospitalier de Bayeux, Bayeux, France.
FAU - Galais, Marie-Pierre
AU  - Galais MP
AD  - Medical Oncology Department, Centre Francois Baclesse, Caen, France.
FAU - Florescu, Carmen
AU  - Florescu C
AD  - Medical Oncology Department, Centre Francois Baclesse, Caen, France.
FAU - Schott, Roland
AU  - Schott R
AD  - Medical Oncology Department, Centre Paul Strauss, Strasbourg, France.
FAU - Le Mauff, Brigitte
AU  - Le Mauff B
AD  - Laboratory of Immunology and Immunopathology, CHU de Caen, Caen, France.
FAU - Gervais, Radj
AU  - Gervais R
AD  - Medical Oncology Department, Centre Francois Baclesse, Caen, France.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20161024
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 37341-29-0 (Immunoglobulin E)
RN  - PQX0D8J21J (Cetuximab)
SB  - IM
MH  - Cetuximab/*immunology
MH  - Drug Hypersensitivity/blood/*epidemiology/immunology
MH  - Female
MH  - France/epidemiology
MH  - Humans
MH  - Immunoglobulin E/*blood
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Risk Factors
PMC - PMC5306475
OTO - NOTNLM
OT  - anaphylaxis
OT  - anti-immunoglobulin E antibodies
OT  - cetuximab
OT  - hypersensitivity
EDAT- 2016/10/26 06:00
MHDA- 2018/01/06 06:00
PMCR- 2018/03/01
CRDT- 2016/09/25 06:00
PHST- 2016/01/25 00:00 [received]
PHST- 2016/08/28 00:00 [revised]
PHST- 2016/09/18 00:00 [accepted]
PHST- 2016/10/26 06:00 [pubmed]
PHST- 2018/01/06 06:00 [medline]
PHST- 2016/09/25 06:00 [entrez]
PHST- 2018/03/01 00:00 [pmc-release]
AID - BCP13140 [pii]
AID - 10.1111/bcp.13140 [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 2017 Mar;83(3):623-631. doi: 10.1111/bcp.13140. Epub 2016 
      Oct 24.